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Rapid proliferation in small cell lung cancer (SCLC) may be
mediated by synthesis of autocrine growth factors. Bombesin
(or its mammalian homologue gastrin releasing peptide,
GRP) may have autocrine function in SCLC (Cuttitta et al.,
1985; Carney et al., 1987) but is not synthesised by the faster
growing variant SCLC lines (Carney et al., 1985). Somato-
medin-C (Sm-C)/insulin-like growth factor-I (IGF-I) is a
basic peptide of 70 amino acids and MW 7.6kD which is
carried in serum by binding proteins of 40-150kD
(Underwood et al., 1986a). It derives mainly from the liver
but also from extrahepatic sites including lung (D'Ercole et
al., 1984). Function as an autocrine growth factor has been
described in several cell systems, including cultured human
fibroblasts (Clemmons et al., 1981) and breast carcinoma
(Huff et al., 1986). Minuto et al (1986) reported high levels
of Sm-C in operative specimens of primary lung tumour
tissue. All 10 samples were adeno- or squamous carcinoma;
no results were given for SCLC, presumably because these
patients rarely come to surgery. Two more recent studies
have reported expression by a human large cell lung cancer
line of genes for multiple growth factors including IGF-II
but not IGF-I (Betsholtz et al., 1987), and the presence of
'insulin-like' molecules in SCLC conditioned medium
(Cuttitta et al., 1987).
We have been working with a high molecular weight
(>10kD) concentrate of classic SCLC conditioned medium
which is mitogenic to both classic and variant SCLC lines
despite being depleted of bombesin/GRP (Macaulay et al.,
1987). The concentrate was found to contain immunoreactive
Sm-C, prompting a survey of human lung tissues and cell
lines.
Operative specimens of lymph node, non-tumoral lung
and pulmonary tumour tissue were obtained with the kind
help of Mr N. Wright, St George's Hospital, London and
Dr B. Addis, Brompton Hospital, London. Postmortem
specimens of non-tumoral lung (4 of 7 samples) were
obtained within 72h with the assistance of Dr R. Carter,
Royal Marsden Hospital, Sutton, Surrey. Samples of each
tissue were stored at - 160°C. We are grateful to Dr D. N.
Carney, Mater Hospital, Dublin for cell lines NCI-H69 and
NCI-H417, to Dr A.F. Gazdar, NCI, Bethesda, USA for
lines NCI-H23, NCI-H125 and NCI-H226, and to Dr G.
Duchesne, ICR, Surrey for cell lines HC12 and HX149. Cell
line ICR-SC17 was derived in our laboratory from a lymph
node biopsy in a 61 year old male smoker with a pulmonary
mass and superior vena caval obstruction (Macaulay et al.,
1987). All cell lines were grown in RPMI medium with 5%
foetal calf serum (FCS). The SCLC cell lines were charac-
terised morphologically and biochemically as previously
described (Carney et al., 1985; Macaulay et al., 1987).
Tissue samples (200-500mg) and cell pellets (2-4 x 106 viable
cells from 4-8 day old cultures) were washed twice in
phosphate buffered saline (PBS). They were resuspended in 4
vol of ice-cold acid ethanol (one part 2N hydrochloric acid
to 7 parts absolute ethanol), homogenised/ultrasonicated
1 min and stored at -20°C. Samples were neutralised with
Tris buffer, and duplicate aliquots underwent radioimmuno-
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assay (RIA) with a disequilibrium (sequential reagent
addition) assay system modified from a previously-described
technique (Baxter et al., 1982; Teale & Marks, 1986). The
RIA used antiserum D193 (a gift from Dr S. Hampton,
University of Surrey) raised in rabbits against biosynthetic
Sm-C conjugated to keyhole limpet haemocyanin. Briefly,
samples were incubated overnight with D193. Addition of
iodinated tracer was followed by a second incubation period
of 5 h. Separation of the antibody-bound fraction was
achieved by polyethylene glycol-accelerated double antibody.
A standard curve was prepared using dilutions of bio-
synthetic Sm-C (kindly donated by Ciba-Geigy). The bio-
synthetic material was shown to be equipotent with both
purified Sm-C and diluted serum extract in its ability to bind
to assay antibodies. Assay sensitivity was calculated as
0.5ngml-1. Pure preparations of proinsulin and IGF-II
(kind gifts respectively of Dr B. Frank, Eli Lilly,
Indianapolis, USA and Dr J. Zapf, Zurich, Switzerland)
exhibited 0.01% and 3.1% cross-reactivity in an assay
system containing only antiserum and tracer. A precision
profile showed coefficients of variation of 25% at
2.5ngml-1, 19% at 5ngml-1, 13% at lOngml-1 and 11%
at 20ngml-1. Samples were also assayed for soluble protein
using the Bio-Rad Protein Assay. Results were expressed as
Sm-Cngmg - protein (Table I).
Immunoreactive Sm-C was detectable in all of 3 classic
and I of 2 variant SCLC cell homogenates. Sm-C was also
present in cell preparations from 2 of 3 non-small cell lung
lines: one squamous carcinoma and one of 2 adeno-
carcinomas. Assay of tissue homogenates revealed Sm-C in
Table I Sm-C in human lung cancer cell lines and tissues
Cell line Designation Sm-C ngmg
(a) Cell lines
HC12 Classic SCLC 14
HX149 Classic SCLC 5
NCI-H69 Classic SCLC 15
ICR-SC17 Variant SCLC 0






Histology no. samples Mean+s.e.m. Range
(b) Tissues
Non-tumoral Lung/7 6+3 0-21
SCLC Primary tumour/2
SCF LN/2b 15+4 10-29
Mediastinal LN/1 J
Squamous Primary tumour/6 9+3 0-21
Adenocarcinoma Primary tumour/4 5+2 0-10
aAnalysis of variance revealed no significant difference in Sm-C
levels between the histological groups.
bSCF LN=supraclavicular lymph node; one of these biopsies was
the source of variant SCLC line ICR-SC17.
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all SCLC samples, including biopsies of primary tumour and
lymph node metastases, one of which had given rise to the
variant line ICR-SC17. Detectable levels were also found in
5 of 6 primary pulmonary squamous carcinomas and 3 of 4
adenocarcinomas (Table I). These results are unlikely to be
false positives given the specificity of the assay and the fact
that sample Sm-C concentrations diluted in parallel with
standard Sm-C.
Weber et al. (1985) used 3H-thymidine uptake to measure
mitogenicity of GRP in classic SCLC. We have adopted a
similar technique to explore the role of Sm-C. Assays were
performed on triplicate samples in 96-well microtitre plates.
Lyophilised biosynthetic Sm-C (Amersham International,
Amersham, UK) was reconstituted in 0.1 M acetic acid and
diluted to working concentration and pH7 with Tris buffer
and PBS. Individual wells received Sm-C in 20,yl to achieve
final concentration of 0.1-500ngml-1. Wells supplemented
with 20,ul PBS served as negative controls. Single cell
suspensions from 4-8 day old cultures were washed in
unsupplemented RPMI and resuspended in the same
medium; each well received 6 x 103 cells in 170pl. The plates
were incubated for 46h, labelled with 3H-thymidine
(Amersham, 0.4,uCi in 10Il PBS per well) and incubated for
a further 24h. Label incorporation into DNA was assessed
by trichloroacetic acid precipitation and liquid scintillation
counting. The results (mean + s.e.m. of 3 wells) were
expressed as % uptake in negative control wells (see Figure 1
and Table II).
Enhancement of DNA synthesis was seen in 2 of 3 classic
SCLC lines, one variant, and in the faster growing of the 2
adenocarcinoma lines. Sm-C 10-100 ngml was sufficient to
cause significant stimulation (P<0.05) of 3H-thymidine
uptake. Maximal effects were seen at 100-300 ngml - ',
amounting to 170-214% increase in uptake over control.
These levels are of the same order as the Sm-C concentration
of normal adult plasma (100-180ngml-1), although in
excess of the 1-20 ngml- concentration said to promote cell
replication in other in vitro systems (Underwood et al.,
1986a). Although biosynthetic Sm-C behaves similarly to the
natural peptide in most radioligand assays (Baxter et al.,
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Figure 1 Effect of biosynthetic Sm-C on 3H-thymidine uptake
by SCLC. (a) Classic line HC12, (b) Variant line ICR-SC17.
*P<0.01 by 2-tailed Dunnett's test.
Table II Effect of biosynthetic Sm-C on 3H-thymidine uptake by
human lung cancer cell lines
Maximally
Levels (ngml-') mitogenic
Cell line Response sigj >control level (ngml-1) % control
HC12 Yes 10-500 100 214+8
HX149 Yes 50-500 300 210+2
NCI-H69 No
ICR-SC17 Yes 100-500 200 207+11
NCI-H226 No -
NCI-H23 Yes 50-500 100 170+2
NCI-H125 No
ap<0.05 by analysis of variance and 2-tailed Dunnett's text (Zar,
1984).
Response to Sm-C, which is presumably mediated by
binding to Sm-C receptors (Morgan et al., 1986), did not
always correlate with cellular synthesis of the factor. Similar
observations have been made regarding SCLC synthesis of,
and response to, bombesin (Carney et al., 1987). Classic
SCLC lines HC12 and HX149 expressed detectable levels of,
and also exhibited a mitogenic response to, Sm-C. Thus in
these lines Sm-C may be functioning as an autocrine growth
factor. Variant line ICR-SC17 responded to Sm-C, but had
undetectable intracellular factor. Sm-C was, however, present
in the tissue sample from which this line was derived,
suggesting that loss of Sm-C production may have been an
in vitro phenomenon. Conversely there were 3 lines (NCI-
H69, classic SCLC; NCI-H226, squamous; NCI-H125,
adenocarcinoma) which expressed intracellular Sm-C but did
not respond in growth assays. Lack of response here might
be explained either by absence of Sm-C receptors, or
alternatively by saturation of existing binding sites by
endogenous factor. Studies are currently in progress to
clarify this point.
Other workers have assessed the effects of somatomedins
on growth of lung cancer cell lines (Simms et al., 1980;
Brower et al., 1986). Three factors may have contributed to
their negative results. First, the factor used was
multiplication-stimulating activity (rat IGF-II; Marquardt et
al., 1981) rather than human Sm-C/IGF-I. Secondly, tests
were carried out in the presence of insulin which might have
activated Sm-C receptors either by direct binding (Morgan et
al., 1986) or by inducing phosphorylation of the unoccupied
Sm-C receptor ('cross-talk'; Taylor, 1986). Finally, the SCLC
line chosen for testing (Simms et al., 1980) was NCI-H69,
which was the only one of 4 SCLC lines we assessed which
failed to respond to human Sm-C. In a more recent study,
IGF-I was shown to enhance the colony forming efficiency
of normal human bronchial epithelial cells and newly
cultured lung adenosquamous carcinoma cells. Established
lung cancer cell lines had not been tested (Siegfried, 1987).
We have not yet examined the effect of Sm-C in
combination with GRP, but note that Weber et al. (1985), in
studying the mitogenicity of GRP in SCLC, performed
assays in the presence of FCS. Results of our RIA suggest
that heat-inactivated FCS provides 40ngml-1 immuno-
reactive Sm-C.
To assess the value of Sm-C as a clinical marker in lung
cancer, we assayed sera from 18 SCLC and 6 non-SCLC
patients (data not shown). No results were above the normal
range; it has been suggested that serum Sm-C levels are more
closely related to nutritional status (Minuto et al., 1986;
Underwood et al., 1986b).
In summary, we have shown that immunoreactive Sm-C is
detectable in primary and metastatic SCLC tissue and in
SCLC cell lines. Biosynthetic Sm-C is mitogenic as shown by
enhancement of 3H-thymidine uptake in classic and variant
SCLC. Most non-small cell lung cancer tissues expressed
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detectable Sm-C. However, none of the non-SCLC lines both
synthesised Sm-C and responded to biosynthetic factor in
growth assays. We conclude that Sm-C may function as an
autocrine growth factor in SCLC. The finding of Sm-C in
fresh tumour tissue suggests that this phenomenon may be
relevant in vivo and offers the potential for new approaches
to therapy. Tumour growth might be inhibited by immuno-
logical means, by antibodies directed against Sm-C (Russell
et al., 1984) or its receptor (Conover et al., 1986) or
pharmacologically, using growth factor analogues or
inhibitors of secretion.
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